Efficacy of peginterferon ALFA-2A (40KD) (PEGASYS) plud ribavirin for 24 weeks in genotype 1 patients with chronic hepatitis C followed by mono or combination therapy for 22 weeks: Preliminary analysis of an open, multicenter, randomized trial
| Autor: | Bronowicki, J.P., Ouzan, D., Asselah, T., Desmorat, H., Zarski, J.P., Foucher, J., Bourliere, M., Renous, C., Tran, A., Melin, P., Hezode, C., Chevallier, M., Bouvier, M., Pawlotsky, J.M., Lonjon-Domanec, I. |
|---|---|
| Zdroj: | In Journal of Hepatology 2003 38 Supplement 2:18-19 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect